These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 34617531)

  • 1. A multidrug-resistant P-glycoprotein assembly revealed by tariquidar-probe's super-resolution imaging.
    Chen J; Li H; Wu Q; Zhao T; Xu H; Sun J; Liang F; Wang H
    Nanoscale; 2021 Oct; 13(40):16995-17002. PubMed ID: 34617531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2).
    Kannan P; Telu S; Shukla S; Ambudkar SV; Pike VW; Halldin C; Gottesman MM; Innis RB; Hall MD
    ACS Chem Neurosci; 2011 Feb; 2(2):82-9. PubMed ID: 22778859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mapping the Binding Site of the Inhibitor Tariquidar That Stabilizes the First Transmembrane Domain of P-glycoprotein.
    Loo TW; Clarke DM
    J Biol Chem; 2015 Dec; 290(49):29389-401. PubMed ID: 26507655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unveiling the Correlation Between the Membrane Assembly of P-gp and Drug Resistance in Multiple Myeloma Using Super-Resolution Fluorescence Imaging.
    Chen J; Du Y; Hou H; Li W; Sun C; Liang F; Wang H
    Anal Chem; 2024 Jul; 96(29):11673-11681. PubMed ID: 38994836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomes.
    Patel NR; Rathi A; Mongayt D; Torchilin VP
    Int J Pharm; 2011 Sep; 416(1):296-9. PubMed ID: 21703341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives.
    Li XQ; Wang L; Lei Y; Hu T; Zhang FL; Cho CH; To KK
    Eur J Med Chem; 2015 Aug; 101():560-72. PubMed ID: 26197160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ex vivo reversal of chemoresistance by tariquidar (XR9576).
    Di Nicolantonio F; Knight LA; Glaysher S; Whitehouse PA; Mercer SJ; Sharma S; Mills L; Prin A; Johnson P; Charlton PA; Norris D; Cree IA
    Anticancer Drugs; 2004 Oct; 15(9):861-9. PubMed ID: 15457126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased permeability-glycoprotein inhibition at the human blood-brain barrier can be safely achieved by performing PET during peak plasma concentrations of tariquidar.
    Kreisl WC; Bhatia R; Morse CL; Woock AE; Zoghbi SS; Shetty HU; Pike VW; Innis RB
    J Nucl Med; 2015 Jan; 56(1):82-7. PubMed ID: 25500831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of the dual ABCB1 and ABCG2 inhibitor tariquidar on the disposition of oral imatinib in mice.
    Gardner ER; Smith NF; Figg WD; Sparreboom A
    J Exp Clin Cancer Res; 2009 Jul; 28(1):99. PubMed ID: 19591692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P-glycoprotein Inhibitor Tariquidar Potentiates Efficacy of Astragaloside IV in Experimental Autoimmune Encephalomyelitis Mice.
    Zhang W; Liu M; Yang L; Huang F; Lan Y; Li H; Wu H; Zhang B; Shi H; Wu X
    Molecules; 2019 Feb; 24(3):. PubMed ID: 30717494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
    Lee TD; Lee OW; Brimacombe KR; Chen L; Guha R; Lusvarghi S; Tebase BG; Klumpp-Thomas C; Robey RW; Ambudkar SV; Shen M; Gottesman MM; Hall MD
    Mol Pharmacol; 2019 Nov; 96(5):629-640. PubMed ID: 31515284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-protein hydrogen bonds govern the inhibition of the ATP hydrolysis of the multidrug transporter P-glycoprotein.
    Chufan EE; Kapoor K; Ambudkar SV
    Biochem Pharmacol; 2016 Feb; 101():40-53. PubMed ID: 26686578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice.
    Hubensack M; Müller C; Höcherl P; Fellner S; Spruss T; Bernhardt G; Buschauer A
    J Cancer Res Clin Oncol; 2008 May; 134(5):597-607. PubMed ID: 17932689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative small-animal PET evaluation of [11C]tariquidar, [11C]elacridar and (R)-[11C]verapamil for detection of P-glycoprotein-expressing murine breast cancer.
    Wanek T; Kuntner C; Bankstahl JP; Bankstahl M; Stanek J; Sauberer M; Mairinger S; Strommer S; Wacheck V; Löscher W; Erker T; Müller M; Langer O
    Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):149-59. PubMed ID: 21983837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lysosomal trapping of a radiolabeled substrate of P-glycoprotein as a mechanism for signal amplification in PET.
    Kannan P; Brimacombe KR; Kreisl WC; Liow JS; Zoghbi SS; Telu S; Zhang Y; Pike VW; Halldin C; Gottesman MM; Innis RB; Hall MD
    Proc Natl Acad Sci U S A; 2011 Feb; 108(6):2593-8. PubMed ID: 21262843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of the P-gp Inhibitor Tariquidar in Rats After Intravenous, Oral, and Intraperitoneal Administration.
    Matzneller P; Kussmann M; Eberl S; Maier-Salamon A; Jäger W; Bauer M; Langer O; Zeitlinger M; Poeppl W
    Eur J Drug Metab Pharmacokinet; 2018 Oct; 43(5):599-606. PubMed ID: 29616423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors.
    Fox E; Widemann BC; Pastakia D; Chen CC; Yang SX; Cole D; Balis FM
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1273-83. PubMed ID: 26486517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interactions of the multidrug resistance modulators tariquidar and elacridar and their analogues with P-glycoprotein.
    Pajeva IK; Sterz K; Christlieb M; Steggemann K; Marighetti F; Wiese M
    ChemMedChem; 2013 Oct; 8(10):1701-13. PubMed ID: 23943604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening compounds with a novel high-throughput ABCB1-mediated efflux assay identifies drugs with known therapeutic targets at risk for multidrug resistance interference.
    Ansbro MR; Shukla S; Ambudkar SV; Yuspa SH; Li L
    PLoS One; 2013; 8(4):e60334. PubMed ID: 23593196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5-Oxo-hexahydroquinoline derivatives as modulators of P-gp, MRP1 and BCRP transporters to overcome multidrug resistance in cancer cells.
    Ranjbar S; Khonkarn R; Moreno A; Baubichon-Cortay H; Miri R; Khoshneviszadeh M; Saso L; Edraki N; Falson P; Firuzi O
    Toxicol Appl Pharmacol; 2019 Jan; 362():136-149. PubMed ID: 30391378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.